

## Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

Alexandre Alanio, Sarah Dellière, Sofiane Fodil, Stéphane Bretagne, Bruno  
Megarbane

► **To cite this version:**

Alexandre Alanio, Sarah Dellière, Sofiane Fodil, Stéphane Bretagne, Bruno Megarbane. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. *The Lancet Respiratory Medicine*, Elsevier, 2020, 8 (6), pp.e48-e49. 10.1016/s2213-2600(20)30237-x . pasteur-02864593

**HAL Id: pasteur-02864593**

**<https://hal-pasteur.archives-ouvertes.fr/pasteur-02864593>**

Submitted on 11 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



1 **High prevalence of putative invasive pulmonary aspergillosis in critically ill**  
2 **COVID-19 patients**

3  
4 Alexandre Alanio,<sup>1,2,3,\*</sup> Sarah Dellière,<sup>1,2,3</sup> Sofiane Fodil,<sup>2,4</sup> Stéphane Bretagne,<sup>1,2,3</sup> Bruno  
5 Mégarbane<sup>2,5,6</sup>

6  
7 <sup>1</sup> Laboratoire de Parasitologie-Mycologie, AP-HP, Groupe Hospitalier Saint-Louis-  
8 Lariboisière-Fernand-Widal, Paris, France

9 <sup>2</sup> Université de Paris, Paris, France

10 <sup>3</sup> Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence  
11 Mycoses Invasives et Antifongiques, URA3012, Paris, France

12 <sup>4</sup> Médecine Intensive Réanimation, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-  
13 Fernand-Widal, Paris, France

14 <sup>5</sup> Réanimation Médicale et Toxicologique, AP-HP, Groupe Hospitalier Saint-Louis-  
15 Lariboisière-Fernand-Widal, Paris, France

16 <sup>6</sup> INSERM UMRS1144, Paris, France

17

18 \* Corresponding author: Dr Alexandre Alanio. Saint Louis Hospital, 1 avenue Claude  
19 Vellefaux, 75475 Paris CEDEX 10, alexandre.alanio@pasteur.fr.

20

21

22 About 5% of coronavirus disease 2019 (COVID-19) patients require intensive care unit (ICU)  
23 management.<sup>1</sup> These patients are at high risk of developing secondary infections including  
24 invasive pulmonary aspergillosis (IPA).<sup>2</sup> First reported with H1N1 influenza, IPA represents a  
25 frequent (20-30%) and early-onset complication (median, 3 days post-ICU admission) in  
26 critically ill influenza patients leading to enhanced illness severity and mortality (40-60%).<sup>3,4</sup>  
27 Most cases have been observed in non-immunocompromised patients, questioning the  
28 applicability of the EORTC-MSG consensus criteria used to define aspergillosis in  
29 immunocompromised patients.<sup>5</sup> Therefore, an algorithm to discriminate *Aspergillus*  
30 colonization from putative IPA was developed in ICU patients based on mycological criteria  
31 combining culture from respiratory specimens and galactomannan detection in the  
32 bronchoalveolar lavage (BAL) and serum.<sup>4,6</sup>

33 Paralleling what has been reported in influenza patients, we designed this prospective  
34 observational study to investigate IPA risk in critically ill COVID-19 patients. The patients  
35 were classified using the EORTC-MSG criteria<sup>5</sup> (if immunocompromised) and the influenza-  
36 associated IPA criteria<sup>4</sup> combined with serum beta-D-glucan and quantitative real-time PCR  
37 (qPCR)<sup>7</sup> performed in the serum and/or pulmonary specimens (if non-immunocompromised).  
38 Putative IPA was considered if (i) *Aspergillus spp.* was identified in BAL culture; or (ii) two  
39 of the following conditions were met, i.e. presence of *Aspergillus spp.* in bronchial aspiration  
40 (BA) culture; positive *Aspergillus fumigatus* qPCR in BAL, BA or serum;<sup>8</sup> galactomannan  
41 index >0.8 in BAL;<sup>5</sup> galactomannan index >0.5 in serum; and beta-D-glucan >80 pg/mL in  
42 serum. Noteworthy, direct examination of respiratory specimens was not performed to avoid  
43 operator contamination.

44 Twenty-seven successive mechanically ventilated COVID-19 patients (18M/9F, median age,  
45 63 years [range, 43-79]) were included. Specimens (20 BALs/7 BAs) were obtained on day3  
46 [1-6] post-intubation. Probable and putative IPAs were diagnosed in one (4%) and eight  
47 patients (30%), respectively (Table 1). Putative IPA diagnosis relied on *Aspergillus*  
48 identification in BAL culture (N=2) and validation of  $\geq 2$  mycological criteria (N=6).

49 History of hypertension was significantly more frequently reported in the IPA patients (7/9  
50 versus 6/18,  $p=0.04$ ). No other significant differences were observed in terms of age,  
51 EORTC-MSG risk factors for IPA, time between onset of symptoms and intubation and times  
52 between onset of symptoms or intubation and *Aspergillus* respiratory specimen collection,  
53 severity, laboratory data, non-COVID CT-scan images, and steroid administration. Antifungal  
54 therapy was initiated in 2/9 IPA patients. Mortality rate did not differ between IPA and non-  
55 IPA patients (4/9 versus 7/18,  $p=0.9$ ).

56 Here we found putative IPA in almost one third of our mechanically ventilated COVID-19  
57 patients, at a similar rate to that which has been observed in influenza patients.<sup>3,4</sup> One patient  
58 with myeloma presented a probable IPA based on the EORTC criteria<sup>5</sup> with one nodule on  
59 chest X-Rays in addition to the typical COVID-19-attributed lesions.

60 Since CT-scan and BAL are extremely difficult to perform in life-threatening COVID-19  
61 patients, mycological data collection is essential to allow IPA diagnosis. We strongly support  
62 adding beta-D-glucan and qPCR in serum and respiratory specimens to the currently accepted  
63 mycological work-up (i.e. BAL culture and galactomannan testing)<sup>4,6</sup> until the most sensitive  
64 and specific biomarkers are determined in this setting. Serum galactomannan was negative in  
65 8/9 patients, suggesting lesser degree of aspergillus invasiveness or early IPA diagnosis since  
66 respiratory specimens were obtained shortly after intubation. Interestingly, galactomannan  
67 was negative in our two patients receiving hydroxychloroquine thought to have a negative  
68 effect on this measurement.<sup>9</sup>

69 We are convinced that IPA is more likely if at least two mycological criteria are met, such as  
70 in six of our patients. One patient presented positive serum beta-D-glucan (>80pg/mL) and  
71 galactomannan index (>0.5) without *Aspergillus* detection in the BAL. Three others had  
72 *Aspergillus fumigatus* culture without positive qPCR detection or galactomannan antigen in  
73 the BAL or BA. Not considering positive culture alone as a diagnostic criterion in accordance  
74 with what is currently accepted,<sup>4,6</sup> would have resulted in underestimating the frequency of  
75 putative IPA (22% rather than 30% in our study).

76 Despite similar IPA rates in critically ill COVID-19 and influenza patients, the contribution of  
77 *Aspergillus* to the patient presentation in each illnesses may be different. In our IPA patients,  
78 death including in the two patients who received anti-*Aspergillus* treatment was not related to  
79 aspergillosis but to bacterial septic shock complicated by multiorgan failure.

80 Consistent with others,<sup>10</sup> our findings support systematic screening for *Aspergillus* infection  
81 markers in critically ill COVID-19 patients. Although oseltamivir-induced inhibition of the  
82 host neuraminidase activity has been suggested as possible molecular mechanism leading to  
83 decreased anti-*Aspergillus* protective immunity in influenza patients, the exact reasons for  
84 increased vulnerability of the COVID-19 patient to *Aspergillus* remain to be determined as  
85 well as *Aspergillus* contribution to COVID-19-related lung inflammation.

86

87

## 88 **Conflict of interest**

89 The authors declare no conflict of interest

90

91 **Ethics**

92 This study was part of the COVID-ICU registry and the French COVID-19 cohort registry  
93 conducted by the REACTing consortium and directed by INSERM and ISARIC. Our  
94 institutional ethics committee approved the study (N<sup>o</sup>, IDRCB, 2020-A00256-33; CPP, 11-20  
95 20.02.04.68737). When possible, signed informed consent was obtained from the patients or  
96 the next of kin.

97

98 **References**

99 1- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus  
100 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From  
101 the Chinese Center for Disease Control and Prevention. *JAMA* 2020.  
102 DOI:10.1001/jama.2020.2648.

103 2- Lescure F-X, Bouadma L, Nguyen D, *et al.* Clinical and virological data of the first cases  
104 of COVID-19 in Europe: a case series. *Lancet Infect Dis* 2020. DOI:10.1016/s1473-  
105 3099(20)30200-0.

106 3- Wauters J, Baar I, Meersseman P, *et al.* Invasive pulmonary aspergillosis is a frequent  
107 complication of critically ill H1N1 patients: a retrospective study. *Intens Care Med* 2012; **38**:  
108 1761–8.

109 4- Schauwvlieghe AFAD, Rijnders BJA, Philips N, *et al.* Invasive aspergillosis in patients  
110 admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet*  
111 *Respir Medicine* 2018; **6**: 782–92.

112 5- Donnelly JP, Chen SC, Kauffman CA, *et al.* Revision and Update of the Consensus  
113 Definitions of Invasive Fungal Disease From the European Organization for Research and  
114 Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin*  
115 *Infect Dis Official Publ Infect Dis Soc Am* 2019. DOI:10.1093/cid/ciz1008.

116 6- Blot SI, Taccone FS, Abeele A-MV den, *et al.* A Clinical Algorithm to Diagnose Invasive  
117 Pulmonary Aspergillosis in Critically Ill Patients. *Am J Resp Crit Care* 2012; **186**: 56–64.

- 118 7- White P, Alanio A, Cruciani M, *et al.* Nucleic Acid Tools for Invasive Fungal Disease  
119 Diagnosis. *Curr Fungal Infect Rep* 2020; **14**: 76–88.
- 120 8- Alanio A, Menotti J, Gits-Muselli M, *et al.* Circulating *Aspergillus fumigatus* DNA Is  
121 Quantitatively Correlated to Galactomannan in Serum. *Front Microbiol* 2017; **8**: 2040.
- 122 9- Verweij PE, Gangneux JP, Bassetti M, *et al.* Diagnosing COVID-19 associated pulmonary  
123 aspergillosis. *Lancet Microbe* 2020. DOI: [https://doi.org/10.1016/S2666-5247\(20\)30027-6](https://doi.org/10.1016/S2666-5247(20)30027-6)..
- 124 10- Koehler P, Cornely OA, Böttiger BW, *et al.* COVID-19 Associated Pulmonary  
125 Aspergillosis. *Mycoses* 2020. DOI:10.1111/myc.13096

126 **Table 1.** Clinical characteristics of nine critically ill COVID-19 patients with probable (N=1) and putative invasive pulmonary aspergillosis (IPA, N=8)

Patients (gender, age)	Risk factors of severe COVID-19	EORTC risk factors	APACHE II score	Thoracic CT-scan/X-Ray*	Anti-COVID-19 therapies	Steroids to treat pneumonia†	Renal replacement therapy	Vasopressor	Pulmonary specimen§	IPA diagnosis						Number of mycological criteria	Antifungal therapy	Outcome
										BAL Culture‡	BAL/BA qPCR‡	BAL galactomannan index	Serum qPCR‡	beta-D-glucan (pg/mL)	Serum galactomannan index			
<b>Putative IPA patients</b>																		
Pt1 (M, 53)	HT, obesity, IHD	None	26	Typical COVID-19	LPV/RTV	Yes	Yes	Yes	BAL	-	-	0.89	-	523	0.13	2	None	Alive
Pt2 (F, 59)	HT, diabetes, obesity	None	16	Typical COVID-19	LPV/RTV, AZI	No	No	Yes	BAL	+	-	0.03	-	ND	0.04	1	None	Alive
Pt3 (F, 69)	HT, obesity	None	11	Typical COVID-19	LPV/RTV	Yes	No	Yes	TA	+	23.9	ND	-	7,8	0.03	2	None	Alive
Pt4 (F, 63)	HT, diabetes, IHD	None	20	Typical COVID-19	LPV/RTV	Yes	Yes	Yes	BAL	-	-	0.15	ND	105	0.51	2	None	Death (day0)
Pt5 (M, 43)	Asthma	Steroids	8	Typical COVID-19	AZI	No	No	No	BAL	+	-	0.12	-	7	0.04	1	None	Alive
Pt6 (M, 79)	HT	None	16	Typical COVID-19, segmental	LPV/RTV, HCQ, AZI	Yes	No	Yes	BAL	+	34.5	0.05	-	23	0.02	2	None	Alive

				lung atelectasis														
Pt7 (M, 77)	HT, asthma	None	25	Typical COVID-19, emphysema	LPV/RTV, HCQ, AZI	Yes	Yes	Yes	BAL	+	29.0	3.91	-	135	0.37	3	VRC	Death (day18)
Pt8 (F, 75 yr)	HT, diabetes	None	21	Typical COVID-19	LPV/RTV, AZI	Yes	No	Yes	BAL	+	31.7	0.36	-	450	0.37	3	CSP	Death (day11)
<b>Probable IPA patient</b>																		
Pt9 (M, 47)	None	Myeloma, steroids	10	Typical COVID-19 + one peripheral nodule	No	No	No	Yes	TA	+	-	ND	-	14	0.09	1	None	Death (day3)

127 HT, hypertension; IHD, ischemic heart disease; LPV/RTV, lopnavir/ritonavir combination; AZI, azithromycin; HCQ, hydroxychloroquine; IPA, invasive pulmonary  
128 aspergillosis; VRC, voriconazole; CSP, caspofungin; EORTC, European Organization for Research and Treatment of Cancer; †Steroid regimen, dexamethasone intravenous  
129 dose of 20 mg once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10; ‡Culture (-, negative; +, positive with *Aspergillus fumigatus* identification);  
130 †qPCR, quantitative real-time PCR (-, negative; if positive, number of quantification cycles) Thoracic CT-scan/X-Ray\*: Thoracic Ct scan was performed in Pt3, Pt4, Pt5, five  
131 days (median) before respiratory specimens. Pulmonary specimen<sup>§</sup>: BAL, Bronchoalveolar lavage; BA, Bronchial Aspiration; No endotracheal/endobronchial lesion was  
132 observed.